EMA Considers Cracking Down On Late Filings From Companies By Auto-Releasing Rapporteurs

The European Medicines Agency is monitoring the frequency with which it must re-appoint experts to assess EU drug filings due to companies' failure to submit their applications as scheduled, thereby disrupting the evaluation process. It warns action may be needed if the “situation worsens.”